Explore Stanford technologies available for licensing:

In 2021, almost 200,000 patients were diagnosed with leukemia and other blood and immune diseases in the US.

Stanford researchers have developed the first ex vivo bone marrow niche capable of sustaining normal and diseased hematopoietic cells long-term.

Anti-mouse endoglin MAb MJ7/18.
A rat IgG2A MAb recognizing mouse endoglin. In the mouse, endoglin serves as a specific endothelial cell differentiation antigen. Endoglin has been implicated as TGFb3-binding molecule.

Hybridoma 4H9 can be used as an antileukocyte reagent capable of recognizing T-cell leukemia and distinguishing it from other forms of acute leukemia.

Researchers in Dr. Anton Wyss-Coray's lab have identified a new therapeutic avenue for treatment of age-related neurodegenerative diseases. Cerebrovascular changes and inflammation are key features of brain aging and neurodegeneration.

Stanford scientists have discovered a new immunotherapeutic target for treating lung cancer and fibrotic lung disease.

SARS-CoV2 is known to gain entry into epithelial cells through the association of its viral spike protein with the ACE2 receptor, which is widely expressed on epithelial cell types.

Stanford researchers have developed a powerful immune-based gene expression signature that accurately predicts severe outcomes and all-cause mortality across high-risk populations, enabling personalized treatment selection and advancing precision medicine in critical illnesses

MAb, DATK44, induces homotypic aggregation of TK1 cells (a CD8 lymphoma). The glycoprotein recognized by DATK44 is of approximate m.w.

Background

Researchers at Stanford have developed a method of preventing Graft versus Host Disease (GVHD) by inhibiting a specific immune receptor. GVHD is a major debilitating complication of transplantation.

Scientists in Dr. Howard Chang's lab have developed ESCAPE-seq (Enhanced Single Chain Antigen Presentation sequencing) to identify novel neoantigen sequences for the development of immunotherapies.

Targeted protein degradation is an emerging strategy for the elimination of classically undruggable proteins. Mucins are known to be involved in tumor-progressive pathways but are difficult to target using small molecules and antibodies.

MECA-32

This invention describes a highly sensitive technique for proximity-probe based detection of one or more analytes in a sample.